{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:24:36Z","timestamp":1791998676966,"version":"4.4.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"am","delay-in-days":285,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bone.2020.115523","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T21:32:37Z","timestamp":1593725557000},"page":"115523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Bisphosphonates in common pediatric and adult bone sarcomas"],"prefix":"10.1016","volume":"139","author":[{"given":"Marie-Francoise","family":"Heymann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Lezot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115523_bb0005","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00223-017-0372-2","article-title":"Biology of bone sarcomas and new therapeutic developments","volume":"102","author":"Brown","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115523_bb0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0959-8049(01)00004-1","article-title":"Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study","volume":"37","author":"Stiller","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0015","first-page":"49","article-title":"RANKL\/RANK\/OPG: new therapeutic targets in bone tumours and associated osteolysis","volume":"1704","author":"Wittrant","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bone.2020.115523_bb0020","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1158\/0008-5472.CAN-06-4130","article-title":"Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption","volume":"67","author":"Lamoureux","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0025","first-page":"2333","article-title":"Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling","volume":"7","author":"Crenn","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0030","first-page":"279","article-title":"Bone tumor environment as a potential therapeutic target in Ewing sarcoma","volume":"33","author":"Redini","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bone.2020.115523_bb0035","doi-asserted-by":"crossref","first-page":"932451","DOI":"10.1155\/2011\/932451","article-title":"The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumor growth and also a source of new therapeutic targets","volume":"2011","author":"David","year":"2011","journal-title":"Sarcoma"},{"key":"10.1016\/j.bone.2020.115523_bb0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejcb.2017.01.003","article-title":"Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip","volume":"96","author":"Tellez-Gabriel","year":"2017","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.bone.2020.115523_bb0045","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.bbadis.2013.01.001","article-title":"Loss of connexin43 expression in Ewing\u2019s sarcoma cells favors the development of the primary tumor and the associated bone osteolysis","volume":"1832","author":"Talbot","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bone.2020.115523_bb0050","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3389\/fonc.2019.01342","article-title":"The emerging roles of extracellular vesicles in osteosarcoma","volume":"9","author":"Perut","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bone.2020.115523_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194805","article-title":"Tumour-derived extracellular vesicles (EVs): a dangerous \u201cmessage in a bottle\u201d for bone","volume":"20","author":"Cappariello","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2020.115523_bb0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fonc.2018.00133","article-title":"Transforming growth factor-\u03b2 signaling plays a pivotal role in the interplay between osteosarcoma cells and their microenvironment","volume":"8","author":"Verrecchia","year":"2018","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bone.2020.115523_bb0065","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1359-6446(04)03265-9","article-title":"Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools","volume":"10","author":"Heymann","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bone.2020.115523_bb0070","first-page":"337","article-title":"Bisphosphonates: new therapeutic agents for the treatment of bone tumors","volume":"10","author":"Heymann","year":"2004","journal-title":"Mol. Med."},{"key":"10.1016\/j.bone.2020.115523_bb0075","unstructured":"S.H. Ralston. Bisphosphonates in the management of Paget's disease. Bone, (https:\/\/doi.org\/10.1016\/j.bone.2020.115465)."},{"key":"10.1016\/j.bone.2020.115523_bb0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1089\/jayao.2016.0078","article-title":"Monocytes, macrophages, and osteoclasts in osteosarcoma","volume":"6","author":"Kelleher","year":"2017","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"10.1016\/j.bone.2020.115523_bb0085","doi-asserted-by":"crossref","first-page":"103711","DOI":"10.1016\/j.cellimm.2017.10.011","article-title":"The contribution of immune infiltrates and the locl microenvironment in the pathogenesis of osteosarcoma","volume":"343","author":"Heymann","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bone.2020.115523_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115523_bb0095","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-09-0426","article-title":"High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties","volume":"15","author":"Pozzi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0100","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bone.2007.05.002","article-title":"Acute phase response and mineral status following low dose intravenous zoledronic acid in children","volume":"41","author":"Munns","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115523_bb0105","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/jbmr.453","article-title":"Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient","volume":"26","author":"Battaglia","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115523_bb0110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02555748","article-title":"Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat","volume":"38","author":"Schenk","year":"1986","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115523_bb0115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF02547219","article-title":"Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats","volume":"11","author":"Schenk","year":"1973","journal-title":"Calcified Tissue Res."},{"key":"10.1016\/j.bone.2020.115523_bb0120","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.ejca.2013.03.018","article-title":"Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group","volume":"49","author":"Goldsby","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bone.2014.08.018","article-title":"Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies","volume":"68","author":"L\u00e9zot","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115523_bb0130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115523_bb0135","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1535-7163.MCT-07-0546","article-title":"Zoledronic acid inhibits osteosarcoma growth in an orthotopic model","volume":"6","author":"Dass","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bone.2020.115523_bb0140","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158005","article-title":"Combination therapy with zoledronic acid and parathyroid hormone improves bone architecture and strength following a clinically-relevant dose of stereotactif radiation therapy for local treatment of canine osteosarcoma in athymic rat","volume":"11","author":"Curtis","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2020.115523_bb0150","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10585-011-9377-9","article-title":"Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice","volume":"28","author":"Wolfe","year":"2011","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bone.2020.115523_bb0155","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/cncr.21530","article-title":"Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice","volume":"104","author":"Ory","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0160","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bone.2020.115523_bb0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ijc.25051","article-title":"Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model","volume":"127","author":"Labrinidis","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0170","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13569-016-0046-2","article-title":"Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients","volume":"6","author":"Conry","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.bone.2020.115523_bb0175","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","article-title":"Sarcoma Group of UNICANCER; French Society of Pediatric Oncology (SFCE); French Sarcoma Group (GSF-GETO), zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomized multicentre, open-label, phase 3 trial","volume":"17","author":"Piperno-Neuman","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bone.2020.115523_bb0180","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.12659\/MSM.913236","article-title":"Addition of zoledronate to chemotherapy in patients with osteosarcoma treated with limb-sparing surgery: a phase III clinical trial","volume":"25","author":"Li","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.bone.2020.115523_bb0185","first-page":"434","article-title":"The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis","volume":"1826","author":"Endo-Munoz","year":"2012","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.bone.2020.115523_bb0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1182\/blood-2009-08-237628","article-title":"Osteoclasts are important for bone angiogenesis","volume":"115","author":"Cackowski","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bone.2020.115523_bb0195","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3389\/fimmu.2019.01408","article-title":"Immune function and diversity of osteoclasts in normal and pathological conditions","volume":"10","author":"Made","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bone.2020.115523_bb0200","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.trecan.2019.10.007","article-title":"Metabolic regulation of macrophage polarization in cancer","volume":"5","author":"Mehla","year":"2019","journal-title":"Trends Cancer."},{"key":"10.1016\/j.bone.2020.115523_bb0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/2159-8290.CD-14-0621","article-title":"Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer","volume":"5","author":"Junankar","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bone.2020.115523_bb0210","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-10-2047","article-title":"Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents","volume":"17","author":"Buddingh","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0215","doi-asserted-by":"crossref","first-page":"78343","DOI":"10.18632\/oncotarget.13055","article-title":"Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma","volume":"7","author":"Dumars","year":"2016","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.bone.2020.115523_bb0220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.18632\/oncotarget.9497","article-title":"Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts","volume":"8","author":"Comito","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.bone.2020.115523_bb0225","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1096\/fj.201801791RR","article-title":"Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw","volume":"33","author":"Zhu","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.bone.2020.115523_bb0230","doi-asserted-by":"crossref","unstructured":"A. Gomez-Brouchet, C. Illac, J. Gilhodes, C. Bouvier, S. Aubert, J.M. Guinebretiere, B. Marie, F. Larousserie, N. Entz-Werl\u00e9, G. de Pinieux, T. Filleron, V. Minard, V. Minville, E. Mascard, F. Gouin, M. Jimenez, M.C. Ledeley, S. Piperno-Neumann, L. Brugieres, F. R\u00e9dini, CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: an immunohistochemical analysis of the biopsies from the French OS2006 phase 3 trial. Oncoimmunology 6 (2017) e1331193.","DOI":"10.1080\/2162402X.2017.1331193"},{"key":"10.1016\/j.bone.2020.115523_bb0235","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bone.2009.08.010","article-title":"The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro","volume":"45","author":"Mitrofan","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115523_bb0240","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bcp.2009.10.003","article-title":"Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells","volume":"79","author":"R\u00e4ikk\u00f6nen","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bone.2020.115523_bb0245","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2020.115523_bb0250","first-page":"822","article-title":"Amplification of \u03b3\u03b4 T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate","volume":"28","author":"Li","year":"2012","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.bone.2020.115523_bb0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.intimp.2015.06.002","article-title":"Trastuzumab enhanced the cytotoxicity of V\u03b39V\u03b42 T cells against zoledronate-sensitized osteosarcoma cells","volume":"28","author":"Liu","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bone.2020.115523_bb0260","first-page":"1195","article-title":"Gammadelta T cells stimulated by zoledronate kill osteosarcoma cells","volume":"26","author":"Jiang","year":"2010","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.bone.2020.115523_bb0265","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jor.21579","article-title":"Sensitization of human osteosarcoma cells to V\u03b39V\u03b42 T-cells-mediated cytotoxicity by zoledronate","volume":"30","author":"Li","year":"2012","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bone.2020.115523_bb0270","doi-asserted-by":"crossref","unstructured":"S. Wang, H. Li, C. Ye, P. Lin, B. Li, W. Zhang, L. Sun, Z. Wang, D. Xue, W. Teng, X. Zhou, N. Lin, Z. Ye, Vaproic acid combined with zoledronic acid enhanced gd T cell-mediated cytotoxicity against osteosarcoma cells via the accumulation of mevalonated pathway intermediate. Front. Immunol. 9 (2018) 9:377.","DOI":"10.3389\/fimmu.2018.00377"},{"key":"10.1016\/j.bone.2020.115523_bb0275","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.trecan.2017.06.003","article-title":"\u03b3\u03b4 T Cells: unexpected regulators of cancer development and progression","volume":"3","author":"Fleming","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0280","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4149\/neo_2018_181128N904","article-title":"Zoledronic acid modulates human osteosarcoma cells proliferation via GSK-3\u03b2 activation","volume":"66","author":"Li","year":"2019","journal-title":"Neoplasma"},{"key":"10.1016\/j.bone.2020.115523_bb0285","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1054\/bjoc.2000.1679","article-title":"Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line","volume":"84","author":"Mackie","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0290","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00001813-200106000-00007","article-title":"The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro","volume":"12","author":"Sonnemann","year":"2001","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.bone.2020.115523_bb0295","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1290\/1543-706X(2004)040<0113:TEOTBA>2.0.CO;2","article-title":"The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro","volume":"40","author":"Farese","year":"2004","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.bone.2020.115523_bb0300","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.canlet.2005.06.041","article-title":"The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis","volume":"238","author":"Horie","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bone.2020.115523_bb0310","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.bjp.0706373","article-title":"The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells","volume":"146","author":"Inoue","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bone.2020.115523_bb0315","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cellimm.2007.11.005","article-title":"Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells","volume":"249","author":"Muraro","year":"2007","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bone.2020.115523_bb0320","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/jor.20129","article-title":"Anticancer effects of zoledronic acid against human osteosarcoma cells","volume":"24","author":"Kubista","year":"2006","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bone.2020.115523_bb0325","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1055\/s-2008-1078753","article-title":"Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells","volume":"40","author":"Tenta","year":"2008","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.bone.2020.115523_bb0330","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/mol.106.028837","article-title":"Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status","volume":"71","author":"Ory","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bone.2020.115523_bb0335","first-page":"285","article-title":"Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM\/Chk1\/cdc25 pathway in human osteosarcoma cells","volume":"31","author":"Iguchi","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bone.2020.115523_bb0340","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S8756-3282(03)00223-0","article-title":"Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis","volume":"33","author":"Evdokiou","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115523_bb0345","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1756-9966-28-105","article-title":"Risedronate inhibits human osteosarcoma cell invasion","volume":"28","author":"Xin","year":"2009","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0350","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/pbc.20019","article-title":"Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines","volume":"42","author":"Cheng","year":"2004","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-4804(03)00086-6","article-title":"Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate","volume":"111","author":"Heikkil\u00e4","year":"2003","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.bone.2020.115523_bb0360","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.18632\/oncotarget.7138","article-title":"Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bone.2020.115523_bb0365","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1582-4934.2008.00141.x","article-title":"Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells","volume":"12","author":"Ory","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bone.2020.115523_bb0370","first-page":"625","article-title":"Development of stemness in cancer cell lines resistant to the anticancer effects of zoledronic acid","volume":"36","author":"Yoshiyama","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0375","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canlet.2016.11.019","article-title":"Cancer stem cells in osteosarcoma","volume":"386","author":"Brown","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bone.2020.115523_bb0380","first-page":"3565","article-title":"Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid","volume":"30","author":"Morii","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0385","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma","volume":"96","author":"Horie","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0390","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2006.10.004","article-title":"Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells","volume":"250","author":"Benassi","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bone.2020.115523_bb0395","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3858\/emm.2011.43.3.016","article-title":"Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation","volume":"43","author":"Moon","year":"2011","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bone.2020.115523_bb0400","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1158\/1078-0432.CCR-15-1925","article-title":"Blocking HSP90 addiction inhibits tumor cell proliferation, metastasis development, and sysnergistically acts with zoledronic acid","volume":"22","author":"Ory","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0405","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.18632\/oncotarget.2308","article-title":"Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma","volume":"5","author":"Lamoureux","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bone.2020.115523_bb0410","doi-asserted-by":"crossref","unstructured":"C.C. Wu, Y.F. Huang, C.P. Hsieh, P.J. Chueh, Y.L. Chen, Combined use of zoledronic acid augments ursolic acid-induced apoptosis in human osteosarcoma cells through enhanced oxidative stress and autophagy. Molecules 21 (2016) pii: E1640.","DOI":"10.3390\/molecules21121640"},{"key":"10.1016\/j.bone.2020.115523_bb0415","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1158\/0008-5472.CAN-10-0578","article-title":"Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process","volume":"70","author":"Moriceau","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0420","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00280-007-0580-y","article-title":"Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells","volume":"62","author":"Kubo","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bone.2020.115523_bb0425","first-page":"2713","article-title":"Combined effects of bisphosphonate and radiation on osteosarcoma cells","volume":"30","author":"Ryu","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0430","doi-asserted-by":"crossref","first-page":"70869","DOI":"10.18632\/oncotarget.12281","article-title":"Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bone.2020.115523_bb0435","first-page":"3","article-title":"Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells","volume":"83","author":"Hoddinott","year":"2019","journal-title":"Can. J. Vet. Res."},{"key":"10.1016\/j.bone.2020.115523_bb0440","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/jop.12442","article-title":"The enhancing effect of a laser photochemotherapy with cisplatin or zoledronic acid in primary human osteoblasts and osteosarcoma cells in vitro","volume":"45","author":"Heymann","year":"2016","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.bone.2020.115523_bb0445","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/cncr.21383","article-title":"Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma","volume":"104","author":"Zhou","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0450","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","article-title":"Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients","volume":"70","author":"Odri","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0455","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1471-2407-14-169","article-title":"Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration","volume":"14","author":"Odri","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0460","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jor.20177","article-title":"Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells","author":"Kubo","year":"2006","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bone.2020.115523_bb0465","first-page":"767","article-title":"F van Valen","volume":"14","author":"Sonnemann","year":"2003","journal-title":"The Bisphosphonate Pamidronate Is a Potent Inhibitor of Ewing\u2019s Sarcoma Cell Growth in Vitro. Anticancer Drugs"},{"key":"10.1016\/j.bone.2020.115523_bb0470","first-page":"955","article-title":"Abujamra","volume":"31","author":"Dos Santo","year":"2014","journal-title":"In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Oncol. Rep."},{"key":"10.1016\/j.bone.2020.115523_bb0475","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3892\/or.2013.2350","article-title":"Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells","volume":"29","author":"Mueller","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bone.2020.115523_bb0480","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/ijc.21951","article-title":"Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival","volume":"119","author":"Gouin","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0485","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/jor.22714","article-title":"Osteoclast inhibition impairs chondrosarcoma growth and bone destruction","volume":"32","author":"Otero","year":"2014","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bone.2020.115523_bb0490","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00264-010-1130-5","article-title":"Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78","volume":"35","author":"Streitbuerger","year":"2011","journal-title":"Int. Orthop."},{"key":"10.1016\/j.bone.2020.115523_bb0495","first-page":"1879","article-title":"Alendronate inhibits growth of high-grade chondrosarcoma cells","volume":"29","author":"Susi","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0500","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1745-7254.2007.00607.x","article-title":"Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line","volume":"28","author":"Lai","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bone.2020.115523_bb0505","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1007\/s13277-015-4615-4","article-title":"V\u03b39V\u03b42 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma","volume":"37","author":"Sun","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.bone.2020.115523_bb0510","first-page":"7","article-title":"Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports","volume":"28","author":"Montella","year":"2009","journal-title":"J. Clin. Cancer Res."},{"key":"10.1016\/j.bone.2020.115523_bb0515","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.ejca.2014.06.003","article-title":"Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone","volume":"50","author":"Gouin","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bone.2020.115523_bb0520","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1634\/theoncologist.2019-0280","article-title":"Adjuvant zoledronic acid in high-risk giant cell tumor of bone: a multicenter randomized phase II trial","volume":"24","author":"Lipplaa","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2020.115523_bb0525","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00586-018-5470-y","article-title":"Bisphosphonate therapy for spinal aneurysmal bone cysts","volume":"27","author":"Kieser","year":"2018","journal-title":"Eur. J. Spine"},{"key":"10.1016\/j.bone.2020.115523_bb0530","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jpc.13768","article-title":"On behalf of the APEG Bone Mineral Working Group, Consensus guidelines on the use of bisphosphonate therapy in children and adolescents","volume":"54","author":"Simm","year":"2018","journal-title":"J. Paediatrics Child Health"},{"key":"10.1016\/j.bone.2020.115523_bb0535","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(94)90069-8","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"343","author":"Liens","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2020.115523_bb0540","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"12","author":"Chapurlat","year":"1997","journal-title":"J. Bone Miner. Re."},{"key":"10.1016\/j.bone.2020.115523_bb0545","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","article-title":"Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment","volume":"35","author":"Chapurlat","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115523_bb0550","first-page":"1314","article-title":"Bisphosphonate therapy in fibrous dysplasia","volume":"12","author":"Lane","year":"1997","journal-title":"Clin. Orthop. Rel. Res."},{"key":"10.1016\/j.bone.2020.115523_bb0555","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1385\/JCD:4:2:167","article-title":"Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia","volume":"4","author":"Parisi","year":"2001","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2020.115523_bb0560","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1515\/JPEM.2006.19.1.75","article-title":"Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood","volume":"19","author":"Chan","year":"2006","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115523_bb0565","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4158\/EP-2018-0328","article-title":"Efficacy and safety of bisphosphonate therapy in McCune-Albright syndrome-related to polyostitic fibrous dysplasia: a single-center experience","volume":"25","author":"Wang","year":"2019","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2020.115523_bb0570","first-page":"327","article-title":"Low-grade central osteosarcoma of distal femur, resembling fibrous dysplasia Word J","volume":"4","author":"Vasiliadis","year":"2013","journal-title":"Orthop."},{"key":"10.1016\/j.bone.2020.115523_bb0575","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.prp.2017.10.018","article-title":"Osteosarcoma arising in fibrous dysplasia, confirmed by mutational analysis of GNAS gene","volume":"214","author":"Sugiura","year":"2018","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bone.2020.115523_bb0580","first-page":"E367","article-title":"Malignant transformation of an aneurysmal bone cyst to fibroblastic osteosarcoma","volume":"45","author":"Kansara","year":"2016","journal-title":"Am. J. Orthop."},{"key":"10.1016\/j.bone.2020.115523_bb0585","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jbspin.2009.01.013","article-title":"Bifocal sarcomatous transformation of Paget's disease: a case report","volume":"76","author":"Mansouri","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bone.2020.115523_bb0590","doi-asserted-by":"crossref","first-page":"942","DOI":"10.5858\/2007-131-942-SAIPDO","article-title":"Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases","volume":"131","author":"Deyrup","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.bone.2020.115523_bb0595","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00428-016-1926-9","article-title":"Giant cell rich osteosarcoma revisited-diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment","volume":"468","author":"Chow","year":"2016","journal-title":"Virchows Arch."},{"key":"10.1016\/j.bone.2020.115523_bb0600","doi-asserted-by":"crossref","unstructured":"N.A. Nadar, N. Margiotta, M. Iafisco, J.J.J.P. van den Beucken, O.C. Boerman, S.C.G. Leeuwenburgh, bisphosphonate-functionalized imaging agents, anti-tumor agents and nanocarriers for treatment of bone cancer. Adv. Healthc. Mater. 6 (2017) 8.","DOI":"10.1002\/adhm.201601119"},{"key":"10.1016\/j.bone.2020.115523_bb0605","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1021\/acs.bioconjchem.9b00210","article-title":"12b80-hydroxybisphosphonate linked doxorubicin: bone targeted dtrategy for treatment of osteosarcoma","volume":"30","author":"David","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bone.2020.115523_bb0610","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12951-016-0233-6","article-title":"Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model","volume":"14","author":"Rudnick-Glick","year":"2016","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.bone.2020.115523_bb0615","doi-asserted-by":"crossref","first-page":"E4601","DOI":"10.1073\/pnas.1603316113","article-title":"Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis","volume":"113","author":"Yin","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2020.115523_bb0620","doi-asserted-by":"crossref","first-page":"25887","DOI":"10.1021\/acsami.7b08108","article-title":"Bisphosphonate-functionalized hydroxyapatite nanoparticles for the delivery of the bromodomain inhibitor JQ1 in the treatment of osteosarcoma","volume":"9","author":"Wu","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bone.2020.115523_bb0625","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.2147\/IJN.S211981","article-title":"Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy","volume":"14","author":"Xi","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bone.2020.115523_bb0630","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.bmcl.2016.12.050","article-title":"Bifunctional bisphosphonate derivatives and platinum complexes with high affinity for bone hydroxyapatite","volume":"27","author":"Sun","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bone.2020.115523_bb0635","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1089\/ten.tea.2016.0001","article-title":"Controlled release of chemotherapeurtic platinum-bisphosphonate complexes from injectable calcium phosphate cements","volume":"22","author":"Farbod","year":"2016","journal-title":"Tissue Eng. Part A"},{"key":"10.1016\/j.bone.2020.115523_bb0640","doi-asserted-by":"crossref","first-page":"17387","DOI":"10.1038\/srep17387","article-title":"Development of alendronate-conjugated poly (lactic-co-glycolic acid)-dextran nanoparticles for active targeting of cisplatin in osteosarcoma","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2020.115523_bb0645","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/1061186X.2013.877467","article-title":"Experiments and synthesis of bone-targeting epirubicin with the water-soluble macromolecular drug delivery systems of oxidized-dextran","volume":"22","author":"Yu","year":"2014","journal-title":"J. Drug Target"},{"key":"10.1016\/j.bone.2020.115523_bb0650","first-page":"2116","article-title":"Targeted antiosteosarcoma methotrexate-bisphosphonate conjugate induces apoptosis of osteosarcoma cells in vitro","volume":"18","author":"Yang","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bone.2020.115523_bb0655","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2217\/nnm-2016-0151","article-title":"Synthesis and evaluation of alendronate-modified gelatin biopolymer as a novel osteotropic nanocarrier for gene therapy","volume":"11","author":"Mekhail","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.bone.2020.115523_bb0660","unstructured":"L. Xing, F.H. Ebetino, R.K. Boeckman, V. Srinivasan, J. Tao, T.K. Sawyer, J. Li, Z. Yao, B.F. Boyce, Targeting anti-cancer agents to bone using bisphosphonates. Bone, in press (doi:https:\/\/doi.org\/10.1016\/j.bone.2020.11549)."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220303033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220303033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:48:30Z","timestamp":1757612910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220303033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":131,"alternative-id":["S8756328220303033"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115523","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonates in common pediatric and adult bone sarcomas","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115523"}}